Beximco Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Beximco Pharmaceuticals has a total shareholder equity of BDT50.4B and total debt of BDT7.4B, which brings its debt-to-equity ratio to 14.7%. Its total assets and total liabilities are BDT70.2B and BDT19.8B respectively. Beximco Pharmaceuticals's EBIT is BDT7.8B making its interest coverage ratio 6.8. It has cash and short-term investments of BDT1.4B.
Key information
14.7%
Debt to equity ratio
৳7.43b
Debt
Interest coverage ratio | 6.8x |
Cash | ৳1.36b |
Equity | ৳50.41b |
Total liabilities | ৳19.81b |
Total assets | ৳70.22b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: BXP's short term assets (BDT21.8B) exceed its short term liabilities (BDT12.1B).
Long Term Liabilities: BXP's short term assets (BDT21.8B) exceed its long term liabilities (BDT7.7B).
Debt to Equity History and Analysis
Debt Level: BXP's net debt to equity ratio (12%) is considered satisfactory.
Reducing Debt: BXP's debt to equity ratio has reduced from 36.7% to 14.7% over the past 5 years.
Debt Coverage: BXP's debt is well covered by operating cash flow (112.7%).
Interest Coverage: BXP's interest payments on its debt are well covered by EBIT (6.8x coverage).